Integrated software and modeling of the impact of plant-derived dietary microRNAs on the immune and nutritional status of children: an integrative in silico study
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Childhood malnutrition remains a major global public health challenge. Plant-based foods such as moringa, dates, tiger nuts, soybeans, and maize contain biologically active microRNAs (miRNAs) that may exert cross-kingdom transcriptomic effects in the human host. The objective of the study was to model in silico interactions between plant miRNAs from a multi-ingredient nutritional porridge and human genes involved in infant immunity and growth. A predictive bioinformatics study was conducted using the miRBase database, miRDB (score ≥80), miRTarBase, and the Database for Annotation, Visualization and Integrated Discovery (DAVID) for functional enrichment analysis. Statistical analyses, including Pearson’s chi-square test, the Mann-Whitney U test, and multivariate logistic regression, were applied to 27,544 miRNA-gene interactions. Among the 27,544 interactions, 7,400 (26.9%) reached a score ≥80, including 100 targeting immunity (n=50) or growth (n=12) genes. Genes of interest showed significantly higher mean scores (87.2±5.1 vs. 69.9±13.3; p<0.01). The miR156 family targeted IRF2BP2, PRKCB, and PAK1 (score 97-99) across four sources. DAVID confirmed 160 enriched pathways (fold enrichment up to ×49.6; p<10−8). Dietary plant miRNAs converge non-randomly toward fundamental pathways for infant immunity and growth, forming a synergistic molecular system warranting experimental validation.
Evangelical University Institute of Cameroon.
How to Cite

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.